HAIXI PHARMA (02637.HK): Trustee buys 394,900 H shares
- Shareholders approved resolution 16, which also authorised the board and/or its authorised persons to handle all matters relating to the scheme.
NewTimeSpace News: On 20 October 2026, Fujian Haixi Pharmaceuticals Co., Ltd. (stock code: 02637) said the trustee appointed for its share award scheme had bought 394,900 H shares in aggregate on the Stock Exchange's secondary market as at 16 October 2026, about 0.502% of the total issued shares as at the date of the announcement.
The shares are held on trust for the scheme's eligible participants and will be used for future grants under the scheme. The scheme was proposed in an announcement on 29 April 2026, set out in a circular on 30 April 2026 and approved by shareholders through resolution 16 at the annual general meeting on 27 May 2026. Further purchases depend on market conditions and are at the discretion of the board, with no assurance as to timing, volume or price.
- HAIXI PHARMA (02637.HK): HX9428 Phase I and Phase II nAMD data show continued BCVA improvement
- HAIXI PHARMA (02637.HK): Oral Retinal Disease Drug HX9428 Files Phase IIa IND for Diabetic Macular Edema; Phase I Data in nAMD Disclosed
- Going Global Weekly Report: Pharma Overseas Expansion Blossoms Across Fronts, A-Share Companies Accelerate Hong Kong Listings - 20260821
- HAIXI PHARMA (02637.HK): HX9428 for Neovascular Age-Related Macular Degeneration Granted Fast Track Designation by US FDA
- HAIXI PHARMA(02637.HK): HX9428 for nAMD Cleared by US‑FDA for Phase II Trial; Positive‑Control Phase II Study Initiated in China
